Evidence map›Paper›PMID 41385096›Full record

ArticleNucleic acids research2026

Medicines, Diseases, Indications, and Contraindications (MeDIC): a foundational resource to support drug repurposing.

Marcello DeLuca, Nico Matentzoglu, Elliott Sharp, Jane Li, Charlie Hempstead, May Lim, Piotr Kaniewski, E Kathleen Carter, Kushal Koirala, Elvin Ding and 11 more

Abstract read
In one paragraph

Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Marcello DeLucaDivision of Chemical Biology and Medicinal Chemistry, University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC 27599, United States.ORCID 0000-0002-4299-3501
Nico MatentzogluSemanticly, Athens 10563, Greece.ORCID 0000-0002-7356-1779
Elliott SharpEvery Cure, Philadelphia, PA 19104, United States.
Jane LiEvery Cure, Philadelphia, PA 19104, United States.
Charlie HempsteadEvery Cure, Philadelphia, PA 19104, United States.
May LimEvery Cure, Philadelphia, PA 19104, United States.
Piotr KaniewskiEvery Cure, Philadelphia, PA 19104, United States.
E Kathleen CarterRenaissance Computing Institute, Chapel Hill, NC 27517, United States.
Kushal KoiralaDivision of Chemical Biology and Medicinal Chemistry, University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC 27599, United States.
Elvin DingDivision of Chemical Biology and Medicinal Chemistry, University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC 27599, United States.
Laurens VijnckEvery Cure, Philadelphia, PA 19104, United States.
Pascal BrokmeierEvery Cure, Philadelphia, PA 19104, United States.
Sabrina ToroDepartment of Genetics, University of North Carolina School of Medicine, Chapel Hill, NC 27599, United States.
Kevin SchaperDepartment of Genetics, University of North Carolina School of Medicine, Chapel Hill, NC 27599, United States.
Jacques VergineEvery Cure, Philadelphia, PA 19104, United States.
Olivia LiDivision of Chemical Biology and Medicinal Chemistry, University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC 27599, United States.
Tudor I OpreaExpert Systems, Inc., Dover, DE 19901, United States.ORCID 0000-0002-6195-6976
David C FajgenbaumEvery Cure, Philadelphia, PA 19104, United States.ORCID 0000-0002-7367-8184
Christopher BizonRenaissance Computing Institute, Chapel Hill, NC 27517, United States.ORCID 0000-0002-9491-7674
Melissa HaendelDepartment of Genetics, University of North Carolina School of Medicine, Chapel Hill, NC 27599, United States.ORCID 0000-0001-9114-8737
Alexander TropshaDivision of Chemical Biology and Medicinal Chemistry, University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC 27599, United States.ORCID 0000-0003-3802-8896

Funding

Advanced Research Projects Agency for Health 140D042490001
6 · The paper itself

Abstract

Drug databases typically aim to provide reference information on medications and their uses but often lack strict definitions of the terms drug (e.g. approved or a clinical candidate) or disease, and do not focus on any specific context of use. The recent emergence of biomedical knowledge graphs, which integrate diverse biomedical data into a contiguous, harmonized knowledge network, has enabled innovation in drug repurposing (identification of novel uses of existing drugs). This objective has created a new set of requirements and challenges for drug databases to be used for generating high-confidence, testable drug repurposing hypotheses. To address this challenge, we have developed MeDIC as an open, foundational database built from government regulatory sources only, which comprises highly curated lists of drugs (including combination therapies), diseases, indications (i.e. drug approvals to treat specific diseases), contraindications, and additional metadata. MeDIC allows for easy maintainability, open-source adaptability, and ongoing updates concordant with updates of primary sources. To facilitate downstream use, MeDIC is provided in a tabulated format, and each drug, disease, indication, or contraindication entry is mapped to multiple ontologies. We offer MeDIC as a web-based, freely accessible (https://medic.renci.org), downloadable (including lists and source code), searchable, and machine learning-friendly resource for patients, providers, and researchers.

Indexed as

Databases, PharmaceuticalDrug RepositioningContraindications, DrugDiseaseHumans

Identifiers

PMID41385096
PMCPMC12807713

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.